Human Immunodeficiency Virus and the Liver: Lessons Learned and Still to Be Learned

Douglas T. Dieterich

doi:10.1055/s-2003-39944

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2003; 23(2): 107-114
DOI: 10.1055/s-2003-39944

Human Immunodeficiency Virus and the Liver: Lessons Learned and Still to Be Learned

Douglas T. Dieterich

Department of Gastroenterology, New York University School of Medicine, New York, New York
Department of Medicine, Mt. Sinai School of Medicine, New York, New York

Abstract

Full Text

References

REFERENCES

1 Larrat S, Stanke-Labesque F, Plage A. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother . 2003; 47 124-129
2 Vogt M W. Interaction between didanosine and ribavirin. Science . 1987; 235 1376-1379
3 Mauss S. Risk factors for hepatic decompensation in cirrhotic patients with HIV-HCV coinfection treated with peg-interferon alfa or interferon alfa and ribavirin or placebo. Presented at the European Congress on AIDS. November 3, 2002; Glasgow, Scotland
4 Esteban R. Treatment of chronic hepatitis in HCV/HIV coinfected patients. Presented at the XIV International AIDS Conference. July 8, 2002; Barcelona, Spain. MoOrB113
5 Dieterich D T. Epoetin alfa treatment of anemic HCV patients allows for maintenance of ribavirin dose, increases hemoglobin levels and improves quality of life (in press). Am J Gastroenterol 2003.
6 Dieterich D T. Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients. J Infect Dis . 2002; 185 S128-S137
7 Nelson M, Portsmouth S, Stebbing J. An open label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS . 2003; 17 F7-F10
8 Benhamou Y, Bochet M, Thibault V. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology . 1999; 30 1302-1306
9 Stapleton J T. GB virus type C/hepatitis G virus. Semin Liver Dis . 2003; 23 137-148
10 Roland M E, Carlson L, Ragni M. Solid organ transplantation in HIV-infected recipients: forty-seven cases in the HAART era. Presented at the XIV International AIDS Conference. July 8, 2002; Barcelona, Spain. Abstract MoOr B1060
11 Pallella F J, Delaney K M, Moorman A C. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med . 1998; 338 853-860
12 Kaplowitz N, Lewis J H, Watkins P B. Did this drug cause my patient's hepatitis?. Ann Intern Med . 2002; 136 480-483
13 Montessori V, Harris J, Montaner J SG. Nucleoside analogue liver toxicity. Semin Liver Dis . 2003; 23 167-172
14 Lewis W, Dalakis M C. Mitochondrial toxicity of antiviral drugs. Nat Med . 1995; 1 417-421
15 Delgado J, Harris M, Tesiorowski A, Montaner J SG. Symptomatic elevations of lactic acid and their response to treatment manipulation in HIV infected individuals-a case series. Clin Infect Dis . 2001; 33 2072-2074
16 Sulkowski M S. Protease inhibitor toxicity. Semin Liver Dis . 2003; 23 183-194
17 Carr A, Samaraas K, Burton S. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS . 1998; 12 F51-58
18 Behrens G, Dejam A, Schmidt H. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS . 1999; 13 F63-F70
19 Sutinen J, Hakkinen A, Westerbacka J. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS . 2002; 16 2183-2193
20 Brunt E M. NASH: definition and pathology. Semin Liver Dis . 2001; 21 3-16
21 Gelato M C. Improved insulin sensitivity with body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr . 2002; 31 163-170
22 Graham D J, Drinkard C R, Shatin D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am J Gastroenterol . 2003; 98 175-179
23 Schambelan M, Benson C, Carr A. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an IAS-USA Panel. J Acquir Immune Defic Syndr . 2002; 31 257-275
24 Cheeseman S H, Havlir D, McLauglin M M. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol . 1995; 8 141-145
25 D'Aquila R T, Hughes M D, Johnson V A. Nevirapine, ziodovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. Ann Intern Med . 1996; 124 1019-1030
26 Riesler R, Servoss J, Sherman K. Incidence of hepatotoxicity and mortality in 21 adult antiretroviral treatment trials ACTG Liver Disease Focus Group. Presented at the IAS 2001. July 8, 2001; Buenos Aires, Argentina. Abstract 43
27 Centers for Disease Control and Prevention. Serious adverse events attributed to nevirapine regimens for post-exposure prophylaxis after HIV exposures-worldwide, 1997-2000. MMWR Morb Mortal Wkly Rept . 2001; 49 1153-1156
28 Van der Horst C. et al .FTC 302 results of a randomized trial. Presented at the Conference on Retroviruses and Opportunistic Infections. February 3, 2001; Chicago, IL. Abstract 18.
29 Stern J O. Nevirapine hepatic safety project. Presented at the XIV International AIDS Conference. July 8, 2002; Barcelona, Spain
30 Yeni P G, Hammer S M, Carpenter C CJ. Antiretroviral treatment for adult HIV infection in 2002 updated recommendations of the IAS-USA panel. JAMA . 2002; 288 222-235
31 van Leth F, Hassink E, Phanphk P. et al .Results of the 2NN study: a randomized comparative trial of first line antitretiviral therapy with regimens containing either nevirapine alone, efavirenz alone, or both drugs combined together with stavudine and lamivudine. Presented at the 10th Conference on Retroviruses and Opportunistic Infections. February 14, 2003; Boston. Abstract 176.
32 Evans W E, McLeod H L. Pharmacogenomics drug disposition, drug targets and side effects. N Engl J Med . 2003; 348 538-549